Our Pricing

Weight Loss Treatment Side Effects: Your Options

Published on: June 03, 2026

Understanding weight loss treatment side effects UK options is essential before starting any prescription medication. At Cured Pharmacy, our UK-registered clinical team provides transparent guidance on the side effect profiles of all licensed treatments, from GLP-1 injections like Mounjaro to oral medications like Orlistat, helping you make an informed choice with confidence.

Understanding GLP-1 Receptor Agonist Side Effects

GLP-1 receptor agonists — including Mounjaro (tirzepatide), Wegovy (semaglutide), and Saxenda (liraglutide) — work by mimicking natural gut hormones that regulate appetite and blood sugar. These medications share a common side effect profile because they slow gastric emptying and affect the digestive system [1].

The most frequently reported side effects are gastrointestinal: nausea affects approximately 30-40% of patients initially, alongside diarrhoea, constipation, and occasional vomiting [1][2]. These symptoms typically emerge during dose escalation and diminish significantly within 4-8 weeks as your body adapts to the medication.

In the STEP trials for semaglutide, 74% of participants reported at least one gastrointestinal event, but only 4.5% discontinued treatment due to side effects — demonstrating that whilst common, these effects are generally manageable [2]. Starting at the lowest licensed dose and following the gradual titration schedule recommended by your UK prescriber substantially reduces symptom severity.

Mounjaro Side Effects: What Clinical Trials Show

Mounjaro (tirzepatide) is the first dual GIP/GLP-1 receptor agonist licensed in the UK, and its side effect profile reflects this dual mechanism. In the SURPASS-1 trial, nausea occurred in 12-18% of patients depending on dose, with diarrhoea affecting 12-14% and constipation 6-7% [3].

What distinguishes Mounjaro from single-pathway GLP-1 medications is the timing and intensity of side effects. Because tirzepatide activates both GIP and GLP-1 receptors, patients often experience milder initial nausea compared to semaglutide, though individual responses vary considerably [3].

Serious adverse events remain rare. Pancreatitis occurred in less than 0.2% of trial participants, and thyroid concerns (including medullary thyroid carcinoma) have only been observed in rodent studies, not human trials [3]. Your UK prescriber will screen for contraindications including personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2 before prescribing.

Managing Mounjaro Side Effects Effectively

Most patients find gastrointestinal symptoms manageable through dietary modifications. Eating smaller, more frequent meals, avoiding high-fat foods during the first few weeks, and staying well-hydrated significantly reduces nausea intensity. If you experience persistent vomiting or signs of dehydration, contact your prescriber immediately — dose adjustment may be appropriate.

Wegovy and Saxenda Side Effects Compared

Wegovy (semaglutide) and Saxenda (liraglutide) are both single-pathway GLP-1 receptor agonists, but their dosing frequency creates different side effect experiences. Wegovy is administered once weekly, producing more stable blood levels and potentially fewer peaks in gastrointestinal symptoms between doses [2].

Saxenda requires daily injection, which some patients find leads to more consistent but persistent mild nausea, particularly during the first two weeks of treatment. In the SCALE trial, 39.3% of liraglutide patients reported nausea versus 13.8% in the placebo group [4].

Both medications carry similar warnings regarding potential pancreatitis, gallbladder disease, and thyroid tumours observed in animal studies. The MHRA requires all GLP-1 medications to include these warnings, though the absolute risk remains very low in human populations. Wegovy's once-weekly dosing often makes it easier to plan around social events where you want to minimise digestive discomfort.

Injection Site Reactions

Local injection site reactions — redness, itching, or mild swelling — occur in approximately 2-5% of patients using GLP-1 injections. Rotating injection sites between your abdomen, thigh, and upper arm, and allowing the pen to reach room temperature before injecting, substantially reduces these reactions. Persistent or worsening site reactions warrant clinical review.

Orlistat Side Effects: A Different Mechanism

Orlistat (available as prescription-strength Xenical 120mg or lower-dose Alli 60mg) works entirely differently from GLP-1 medications. It blocks approximately 25-30% of dietary fat absorption in your intestines, which creates a distinct side effect profile centred on bowel changes [5].

The most common side effects are oily spotting, flatulence with discharge, urgent bowel movements, and fatty or oily stools. These effects are directly proportional to dietary fat intake — patients who consume more than 15-20g of fat per meal experience significantly more pronounced symptoms [5].

Unlike GLP-1 medications where side effects typically diminish over time, Orlistat's gastrointestinal effects persist throughout treatment but can be entirely controlled through dietary fat restriction. Many patients find this motivating, as it provides immediate feedback on dietary choices. Orlistat does not cause nausea, does not require injections, and carries no risk of pancreatitis or thyroid concerns.

Weight Loss Treatment Side Effects UK: Choosing the Right Option

Selecting the appropriate weight loss treatment involves balancing efficacy, side effect tolerance, lifestyle factors, and medical history. Patients with sensitive stomachs or previous gastrointestinal surgery may tolerate Orlistat better than GLP-1 medications, whilst those seeking maximum weight loss and willing to manage initial nausea often prefer Mounjaro or Wegovy.

Your UK prescriber at Cured Pharmacy will assess your complete medical history, current medications, and treatment goals during your free online consultation. Contraindications such as inflammatory bowel disease, chronic malabsorption, or previous pancreatitis significantly influence treatment selection.

Age, BMI, and comorbidities also affect side effect risk. Patients over 65 may experience more pronounced gastrointestinal symptoms with GLP-1 medications, whilst those with diabetes require careful monitoring of blood glucose levels when starting treatment. All prescription weight loss medications available through Cured Pharmacy require clinical assessment by a UK prescriber before dispensing.

Starting Treatment Safely

Every licensed weight loss medication begins at a low starting dose with gradual titration. This evidence-based approach minimises side effects whilst allowing your body to adapt. Mounjaro starts at 2.5mg weekly for four weeks, Wegovy at 0.25mg weekly, and Saxenda at 0.6mg daily, with systematic increases over 4-8 weeks to reach therapeutic doses.

Managing Side Effects: Practical Guidance from UK Pharmacists

Our superintendent pharmacist Tarun Kumar (GPhC 2233073) and clinical team have supported thousands of UK patients through weight loss treatment. The most effective side effect management strategies are surprisingly simple: eat slowly, chew thoroughly, avoid lying down immediately after meals, and stay consistently hydrated.

For GLP-1 injection users, taking your weekly dose on the same day each week, preferably when you have a lighter schedule the following day, helps you plan around potential digestive symptoms. Ginger tea, small amounts of protein with each meal, and avoiding carbonated drinks during the first month all provide measurable relief.

If side effects become intolerable, never simply stop treatment abruptly. Contact your prescriber to discuss dose adjustment, switching to an alternative medication, or implementing a temporary pause. Most side effects are dose-dependent and reversible — finding your optimal dose often resolves persistent symptoms whilst maintaining therapeutic benefit.

Serious side effects requiring immediate medical attention include severe abdominal pain (potential pancreatitis), persistent vomiting with inability to keep fluids down (dehydration risk), vision changes, or signs of allergic reaction. These remain rare but warrant prompt clinical evaluation. Cured Pharmacy patients can contact our clinical team on (+44) 116 4646009 during business hours for guidance.

Scientific References

1. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Rosenstock, J., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143–155. https://doi.org/10.1016/S0140-6736(21)01324-6 [accessed 13 August 2026]
4. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
5. Torgerson, J. S., et al. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Side effect profiles described reflect clinical trial data and may vary between individuals. If you experience severe or persistent side effects, contact your prescriber or seek immediate medical attention.